Irbesartan and Aliskiren Interaction

Understanding the Irbesartan and Aliskiren Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Irbesartan belongs to the Angiotensin II Receptor Blocker (ARB) class and Aliskiren belongs to the Direct Renin Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These drugs both work on the same system in the body, which can lead to dangerously low blood pressure or kidney failure. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Irbesartan has 2 total documented interactions on file in this dataset, and Aliskiren has 28. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid this combination if you have diabetes or kidney problems, and have your doctor check your kidney function regularly. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Irbesartan or Aliskiren based on a web page, speak with your prescriber or pharmacist before making any change.